Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

07.11.17	New Drugs Approved In October (RTTNews)
07.11.17	Sphere Announces Unitholder Meetings (PR Newswire)
02.11.17	For the First Time Ever, There Will be a Full Week Dedicated to Plasminogen Deficiency (PLGD) ! (PR Newswire)
27.10.17	Merck Slips To Loss In Q3, Adj. EPS, Sales Miss View; Lifts FY17 Forecast (RTTNews)
27.10.17	Merck & Co Inc. Reveals 2% Rise In Q3 Earnings (RTTNews)
25.10.17	Avis aux médias - La ministre Hajdu visitera Edmonton pour souligner l'Énoncé économique de l'automne du gouvernement du Canada (PR Newswire)
25.10.17	TSX Venture Exchange Daily Bulletins (PR Newswire)
23.10.17	Astrazeneca, Merck Advance Lynparza In Japan With Second Regulatory Submission (RTTNews)
23.10.17	DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS (RTTNews)
18.10.17	Merck Presents Updated Overall Survival Findings From Phase 3 KEYNOTE-024 Trial (RTTNews)
18.10.17	AstraZeneca, Merck Announce FDA Priority Review For Lynparza SNDA (RTTNews)
12.10.17	ARDX Surges After-hours, MBVX Abuzz, TRVN Keeps Its Focus (RTTNews)
11.10.17	Myant commits $100M to the Advanced Manufacturing Supercluster (PR Newswire)
10.10.17	Merck Acquires 9.9% Stake In KalVista (RTTNews)
29.09.17	Merck Moves Lower After Stopping Development Of Hepatitis C Treatments (RTTNews)
29.09.17	Merck Discontinues MK-3682B, MK-3682C Development Programs For HCV Infection (RTTNews)
27.09.17	Expansion de la couverture d'assurance vie et maladie au Canada en 2016 (PR Newswire)
25.09.17	Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes (RTTNews)
20.09.17	Utilisation des pesticides : Les producteurs maraîchers engagés et confiants (PR Newswire)
18.09.17	Merck gibt Preisträger aus seinem "Grant for Growth Innovation"-Förderprogramm 2017 bekannt (PR Newswire)
18.09.17	Merck KGaA, Darmstadt, Germany Announces Recipients of the Grant for Growth Innovation 2017 (PR Newswire)
18.09.17	Merck Announces Recipients of the Grant for Growth Innovation 2017 (PR Newswire)
11.09.17	Merck Presents KEYTRUDA Phase 3 Study Findings - Quick Facts (RTTNews)
11.09.17	Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance (PR Newswire)
10.09.17	Merck KGaA, Darmstadt, Germany, ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research (PR Newswire)
10.09.17	Merck ‘Grant for Oncology Innovation’ Awards Recognize Recipients for Pushing Boundaries in Oncology Research (PR Newswire)
10.09.17	Merck's KEYTRUDA Continues To Show Overall Survival Benefit Over Chemotherapy (RTTNews)
08.09.17	Merck Presents Data From Three Cohorts Of Registrational, Phase 2 KEYNOTE-059 (RTTNews)
08.09.17	Company Spotlight: Immune Design (RTTNews)
06.09.17	Merck To Buy Rigontec (RTTNews)
05.09.17	Merck Says European Commission Approves KEYTRUDA (RTTNews)
05.09.17	Mavenclad (Cladribine Tablets) Demonstrates Sustained Disease Control over 4 Years with Maximum of Only 20 Days Oral Treatment (PR Newswire)
29.08.17	Biotech Stocks Facing FDA Decision In September (RTTNews)
29.08.17	Merck Reports Results Of REVEAL Outcomes Study Of Anacetrapib - Quick Facts (RTTNews)
25.08.17	European Commission Grants Approval for Mavenclad (Cladribine Tablets) (PR Newswire)
22.08.17	Clinical and Regulatory Progress Boosting Biotech Sector (PR Newswire)
22.08.17	Clinical and Regulatory Progress Boosting Biotech Sector (PR Newswire)
18.08.17	FDA Nod For PFE, New Use For AZN's Ovarian Cancer Drug, ELGX's LEOPARD Hits Goal (RTTNews)
18.08.17	LYNPARZA Gets Additional And Broad Approval In U.S. For Ovarian Cancer (RTTNews)
17.08.17	Race For A New Alzheimer's Drug (RTTNews)
17.08.17	Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi (PR Newswire)
16.08.17	PeopleDoc joins the Inc. 5000 list of fastest-growing private companies (PR Newswire)
15.08.17	Intel And Under Armour CEOs Join Exodus From Trump's Manufacturing Council (RTTNews)
15.08.17	Merck And Under Armour CEOs Resign From Trump's American Manufacturing Council (RTTNews)
14.08.17	Merck CEO Quits President's Council Protesting Charlottesville Incident (RTTNews)
09.08.17	Sanofi Files Suit In U.S. To Defend Its Patent Rights On Lantus (RTTNews)
08.08.17	Merck KGaA Says NICE Issues Positive FAD Recommending Routine NHS Use Of Erbitux (RTTNews)
28.07.17	Merck Q2 Profit Beats Estimates; Worldwide Sales Up 1% (RTTNews)
28.07.17	Merck & Co Inc. Q2 Earnings Rise 7% (RTTNews)
27.07.17	Mandy Moore and Merck Encourage Women to Plan Ahead in Her Life. Her Adventures. Campaign (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11.12.24		Dow Jones-Handel aktuell: Dow Jones verbucht letztendlich Verluste
11.12.24		Schwache Performance in New York: Dow Jones gibt nachmittags nach
11.12.24		Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge
11.12.24		Mittwochshandel in Zürich: SMI letztendlich mit Gewinnen
11.12.24		Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen

11.12.24

Dow Jones-Handel aktuell: Dow Jones verbucht letztendlich Verluste

11.12.24

Schwache Performance in New York: Dow Jones gibt nachmittags nach

11.12.24

Gewinne in New York: Dow Jones verbucht am Mittwochmittag Zuschläge

11.12.24

Mittwochshandel in Zürich: SMI letztendlich mit Gewinnen

11.12.24

Börse London: FTSE 100 zum Ende des Mittwochshandels mit positivem Vorzeichen

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten